TY - JOUR
T1 - Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support
AU - Birati, Edo Y.
AU - Najjar, Samer S.
AU - Tedford, Ryan J.
AU - Houston, Brian A.
AU - Shore, Supriya
AU - Vorovich, Esther
AU - Atluri, Pavan
AU - Urgo, Kimberly
AU - Molina, Maria
AU - Chambers, Susan
AU - Escobar, Nicole
AU - Hsich, Eileen
AU - Estep, Jerry D.
AU - Alexander, Kevin M.
AU - Teuteberg, Jeffrey J.
AU - Chaudhry, Sunit Preet
AU - Ravichandran, Ashwin
AU - Devore, Adam D.
AU - Margulies, Kenneth B.
AU - Hanff, Thomas C.
AU - Zimmer, Ross
AU - Kilic, Arman
AU - Wald, Joyce W.
AU - Vidula, Himabindu
AU - Martens, John
AU - Blumberg, Emily A.
AU - Mazurek, Jeremy A.
AU - Owens, Anjali T.
AU - Goldberg, Lee R.
AU - Alvarez-Garcia, Jesus
AU - Mancini, Donna M.
AU - Moss, Noah
AU - Genuardi, Michael V.
N1 - Publisher Copyright:
© 2020 American Heart Association, Inc.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Background: The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence of complex comorbidities and functional impaired immunity. The objective of this study is to describe the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs. Methods: The Trans-CoV-VAD registry is a multi-center registry of LVAD and cardiac transplant patients in the United States with confirmed COVID-19. Patient characteristics, exposure history, presentation, laboratory data, course, and clinical outcomes were collected by participating institutions and reviewed by a central data repository. This report represents the participation of the first 9 centers to report LVAD data into the registry. Results: A total of 40 patients were included in this cohort. The median age was 56 years (interquartile range, 46-68), 14 (35%) were women, and 21 (52%) were Black. Among the most common presenting symptoms were cough (41%), fever, and fatigue (both 38%). A total of 18% were asymptomatic at diagnosis. Only 43% of the patients reported either subjective or measured fever during the entire course of illness. Over half (60%) required hospitalization, and 8 patients (20%) died, often after lengthy hospitalizations. Conclusions: We present the largest case series of LVAD patients with COVID-19 to date. Understanding these characteristics is essential in an effort to improve the outcome of this complex patient population.
AB - Background: The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence of complex comorbidities and functional impaired immunity. The objective of this study is to describe the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs. Methods: The Trans-CoV-VAD registry is a multi-center registry of LVAD and cardiac transplant patients in the United States with confirmed COVID-19. Patient characteristics, exposure history, presentation, laboratory data, course, and clinical outcomes were collected by participating institutions and reviewed by a central data repository. This report represents the participation of the first 9 centers to report LVAD data into the registry. Results: A total of 40 patients were included in this cohort. The median age was 56 years (interquartile range, 46-68), 14 (35%) were women, and 21 (52%) were Black. Among the most common presenting symptoms were cough (41%), fever, and fatigue (both 38%). A total of 18% were asymptomatic at diagnosis. Only 43% of the patients reported either subjective or measured fever during the entire course of illness. Over half (60%) required hospitalization, and 8 patients (20%) died, often after lengthy hospitalizations. Conclusions: We present the largest case series of LVAD patients with COVID-19 to date. Understanding these characteristics is essential in an effort to improve the outcome of this complex patient population.
KW - COVID-19
KW - SARS-CoV-2
KW - heart failure
KW - hospitalization
KW - outcomes research
KW - ventricular assist device
UR - http://www.scopus.com/inward/record.url?scp=85104748026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104748026&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.120.007957
DO - 10.1161/CIRCHEARTFAILURE.120.007957
M3 - Article
C2 - 33813838
AN - SCOPUS:85104748026
SN - 1941-3297
VL - 14
SP - E007957
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
IS - 4
ER -